Identification of cytokines and signaling proteins differentially regulated by sumatriptan/naproxen

Headache

Volumn 52, Issue 1, 2012, Pages 80-89

  Vause, Carrie V ^a   Durham, Paul L ^a  

^a MISSOURI STATE UNIVERSITY   (United States)

Author keywords

array; naproxen sodium; sumatriptan; the spinal trigeminal nucleus; trigeminal ganglion

Indexed keywords

CAPSAICIN; CILIARY NEUROTROPHIC FACTOR RECEPTOR ALPHA; CYTOKINE; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; INTERLEUKIN 13; INTERLEUKIN 1ALPHA; INTERLEUKIN 5; INTERLEUKIN 6; INTESTINAL CELL KINASE; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NAPROXEN; NAPROXEN PLUS SUMATRIPTAN; NERVE GROWTH FACTOR BETA SUBUNIT; OSTEOPONTIN; PEPTIDE HORMONE; PROLACTIN RECEPTOR; PROTEIN KINASE; RESISTIN; RESISTIN LIKE BETA PROTEIN; SIGNAL PEPTIDE; SUMATRIPTAN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UBIQUITIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BRAIN FUNCTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ABSORPTION; DRUG EFFICACY; INJECTION; MALE; MIGRAINE; NERVE CELL STIMULATION; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FOLDING; RAT; TEMPORAL LOBE; TRIGEMINAL NUCLEUS; TRIGEMINUS GANGLION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CAPSAICIN; CYTOKINES; DRUG COMBINATIONS; DRUG INTERACTIONS; GENE EXPRESSION REGULATION; MALE; NAPROXEN; PROTEIN ARRAY ANALYSIS; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SIGNAL TRANSDUCTION; SUMATRIPTAN; TIME FACTORS; TRIGEMINAL GANGLION; TRIGEMINAL NUCLEUS, SPINAL;

EID: 84856275183     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2011.02048.x     Document Type: Article

References (47)

1. Goadsby P, Lipton R, Ferrari M,. Migraine-current understanding and treatment. N Engl J Med. 2002; 346: 257-270. (Pubitemid 34438866)
2. Hargreaves RJ, Shepheard SL,. Pathophysiology of migraine-new insights. Can J Neurol Sci. 1999; 26 (Suppl. 3): S12-S19. (Pubitemid 29526127)
3. Pietrobon D,. Migraine: New molecular mechanisms. Neuroscientist. 2005; 11: 373-386. (Pubitemid 41040865)
4. Burstein R,. Deconstructing migraine headache into peripheral and central sensitization. Pain. 2001; 89: 107-110. (Pubitemid 32146388)
5. Miller R, Jung H, Bhangoo S, White F,. Cytokine and chemokine regulation of sensory neuron function. Handb Exp Pharmacol. 2009; 194: 417-449.
6. Uceyler N, Schafers M, Sommer C,. Mode of action of cytokines on nociceptive neurons. Exp Brain Res. 2009; 196: 67-78.
7. White F, Jung H, Miller R,. Chemokines and the pathophysiology of neuropathic pain. Proc Natl Acad Sci U S A. 2007; 104: 20151-20158.
8. Hopkins S, Rothwell N,. Cytokines and the nervous system. I: Expression and recognition. Trends Neurosci. 1995; 18: 83-88.
9. Kawasaki Y, Zhang L, Cheng JK, Ji RR,. Cytokine mechanisms of central sensitization: Distinct and overlapping role of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in regulating synaptic and neuronal activity in the superficial spinal cord. J Neurosci. 2008; 28: 5189-5194.
10. Watkins L, Milligan E, Maier S,. Glial proinflammatory cytokines mediate exaggerated pain states: Implications for clinical pain. Adv Exp Med Biol. 2003; 521: 1-21. (Pubitemid 36535161)
11. Wieseler-Frank J, Maier S, Watkins L,. Glial activation and pathological pain. Neurochem Int. 2004; 45: 389-395. (Pubitemid 38625629)
12. Watkins LR, Maier SF,. Beyond neurons: Evidence that immune and glial cells contribute to pathological pain states. Physiol Rev. 2002; 82: 981-1011.
13. Ren K, Dubner R,. Neuron-glia crosstalk gets serious: Role in pain hypersensitivity. Curr Opin Anaesthesiol. 2008; 21: 570-579.
14. Takeda M, Takahashi M, Matsumoto S,. Contribution of the activation of satellite glia in sensory ganglia to pathological pain. Neurosci Biobehav Rev. 2009; 33: 784-792.
15. Ren K,. Neuron, glia and reciprocal relationships in pain processing. Open Pain J. 2009; 2: 7-31.
16. Ren K,. Emerging role of astroglia in pain hypersensitivity. Jpn Dent Sci Rev. 2010; 46: 86.
17. Sarchielli P, Alberti A, Vaianella L, et al,. Chemokine levels in the jugular venous blood of migraine without aura patients during attacks. Headache. 2004; 44: 961-968. (Pubitemid 39532337)
18. Kocer A, Memisogullari R, Domac FM, et al,. IL-6 levels in migraine patients receiving topiramate. Pain Pract. 2009; 9: 375-379.
19. Goadsby PJ, Hargreaves RJ,. Mechanisms of action of serotonin 5-HT1B/D agonists: Insights into migraine pathophysiology using rizatriptan. Neurology. 2000; 55: S8-14.
20. 1B/1D receptor agonistis in migraine. CNS Drugs. 1998; 10: 271-286.
21. Moyer S,. Pharmacokinetics of naproxen sodium. Cephalalgia. 1986; 6 (Suppl. 4): 77-80.
22. Krymchantowski AV,. Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq Neuropsiquiatr. 2000; 58: 428-430. (Pubitemid 30469572)
23. Landy S, White J, Lener SE, McDonald SA,. Fixed-dose sumatriptan/naproxen sodium compared with each monotherapy utilizing the novel composite endpoint of sustained pain-free/no adverse events. Ther Adv Neurol Disord. 2009; 2: 135-141.
24. Mathew NT, Landy S, Stark S, et al,. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache. 2009; 49: 971-982.
25. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA,. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med. 2002; 8: 136-142. (Pubitemid 34155124)
26. Li J, Vause CV, Durham PL,. Calcitonin gene-related peptide stimulation of nitric oxide synthesis and release from trigeminal ganglion glial cells. Brain Res. 2008; 1196: 22-32.
27. Thalakoti S, Patil VV, Damodaram S, et al,. Neuron-glia signaling in trigeminal ganglion: Implications for migraine pathology. Headache. 2007; 47: 1008-1023. (Pubitemid 47057221)
28. Capuano A, De Corato A, Lisi L, Tringali G, Navarra P, Dello Russo C,. Proinflammatory-activated trigeminal satellite cells promote neuronal sensitization: Relevance for migraine pathology. Mol Pain. 2009; 5: 43.
29. Meents JE, Neeb L, Reuter U,. TRPV1 in migraine pathophysiology. Trends Mol Med. 2010; 16: 153-159.
30. Cheng J, Ji R,. Intracellular signaling in primary sensory neurons and persistent pain. Neurochem Res. 2008; 33: 1970-1978.
31. Gao YJ, Ji RR,. Targeting astrocyte signaling for chronic pain. Neurotherapeutics. 2010; 7: 482-493.
32. Guo W, Zingg JM, Meydani M, Azzi A,. Alpha-tocopherol counteracts ritonavir-induced proinflammatory cytokines expression in differentiated THP-1 cells. Biofactors. 2007; 31: 171-179. (Pubitemid 352789885)
33. McMahon SB, Cafferty WB, Marchand F,. Immune and glial cell factors as pain mediators and modulators. Exp Neurol. 2005; 192: 444-462. (Pubitemid 40341688)
34. Milligan ED, Watkins LR,. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci. 2009; 10: 23-36.
35. Gosselin RD, Suter MR, Ji RR, Decosterd I,. Glial cells and chronic pain. Neuroscientist. 2010; 16: 519-531.
36. Sommer C, Kress M,. Recent findings on how proinflammatory cytokines cause pain: Peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett. 2004; 361: 184-187. (Pubitemid 38609247)
37. Khoury CK, Couch JR,. Sumatriptan-naproxen fixed combination for acute treatment of migraine: A critical appraisal. Drug Des Devel Ther. 2010; 4: 9-17.
38. Silberstein SD, Mannix LK, Goldstein J, et al,. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology. 2008; 71: 114-121.
39. Durham PL,. Calcitonin gene-related peptide (CGRP) and migraine. Headache. 2006; 46 (Suppl. 1): S3-S8. (Pubitemid 43794782)
40. Levy D, Jakubowski M, Burstein R,. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT1B/1D receptor agonists. Proc Natl Acad Sci U S A. 2004; 101: 4274-4279. (Pubitemid 38405919)
41. Levy D, Zhang XC, Jakubowski M, Burstein R,. Sensitization of meningeal nociceptors: Inhibition by naproxen. Eur J Neurosci. 2008; 27: 917-922. (Pubitemid 351365179)
42. St-Jacques B, Ma W,. Role of prostaglandin E2 in the synthesis of the pro-inflammatory cytokine interleukin-6 in primary sensory neurons: An in vivo and in vitro study. J Neurochem. 2011; 118: 841-854.
43. Waschbisch A, Fiebich BL, Akundi RS, et al,. Interleukin-1 beta-induced expression of the prostaglandin E-receptor subtype EP3 in U373 astrocytoma cells depends on protein kinase C and nuclear factor-kappaB. J Neurochem. 2006; 96: 680-693.
44. Yang MS, Ji KA, Jeon SB, et al,. Interleukin-13 enhances cyclooxygenase-2 expression in activated rat brain microglia: Implications for death of activated microglia. J Immunol. 2006; 177: 1323-1329.
45. Durham PL, Vause CV, Derosier F, McDonald S, Cady R, Martin V,. Changes in salivary prostaglandin levels during menstrual migraine with associated dysmenorrhea. Headache. 2010; 50: 844-851.
46. Cady RK, Diamond ML, Diamond MP, et al,. Sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea: Satisfaction, productivity, and functional disability outcomes. Headache. 2011; 51: 664-673.
47. Mannix LK, Martin VT, Cady RK, et al,. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: Two randomized controlled trials. Obstet Gynecol. 2009; 114: 106-113.